Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001223098 | SCV001395232 | uncertain significance | Hereditary spastic paraplegia 11 | 2021-12-02 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 1305 of the SPG11 protein (p.Ala1305Gly). This variant is present in population databases (rs746116309, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with SPG11-related conditions. ClinVar contains an entry for this variant (Variation ID: 951235). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome Diagnostics Laboratory, |
RCV001847198 | SCV002105711 | uncertain significance | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002468194 | SCV002763945 | uncertain significance | Amyotrophic lateral sclerosis type 5 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV002468195 | SCV002763946 | uncertain significance | Charcot-Marie-Tooth disease axonal type 2X | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV001223098 | SCV002763947 | uncertain significance | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing |